Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Identification of therapeutic strategies overcoming resistance to apoptosis in pediatric acute myeloid leukemias.
FY 2023-24
Summary
Acute megakaryoblastic leukemia (AMKL) is a rare sub-type of leukemia that primarily affects children. AMKL is commonly associated with genetic alterations which increase the likelihood of therapeutic resistance, ultimately worsening survival rates. Escaping cell death ranks as one of the most dangerous characteristics inherited by cancer cells, thus making it an attractive target for anticancer therapeutics. My research project aims to investigate novel therapeutic strategies that bypass resistance mechanisms associated with decreased expression of specific cell death activators in AMKL models. High-fatality AMKL models have been generated in our lab to emulate the human pathophysiology in the context of mice. I will engineer cell death-resistant models with a gene editing tool. The resistant models will then be treated with bioactive molecules to identify drugs that halt the progression of cancer by bypassing resistance mechanisms. There is a pressing need for treatments that successfully counter therapeutic resistance among pediatric leukemias to increase patient survival rates. My project offers a new perspective to identify novel compounds that target alternative cell death targets, consequently revealing new classes of drugs that could efficiently treat resistant pediatric AMKL.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506256
Name
Spilak Julia
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of therapeutic strategies overcoming resistance to apoptosis in pediatric acute myeloid leukemias.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Megakaryoblastic Leukemia (Amkl); Apoptosis; Bax/Bak1; Bh3 Mimetics; Cbfa2t3-Glis2 Fusion; Crispr Cas9; Mechanism Of Action; Overcoming Cancer Therapeutic Resistance; Pediatric Leukemia; Targeted Therapy
Abstract
Acute megakaryoblastic leukemia (AMKL) is a rare sub-type of leukemia that primarily affects children. AMKL is commonly associated with genetic alterations which increase the likelihood of therapeutic resistance, ultimately worsening survival rates. Escaping cell death ranks as one of the most dangerous characteristics inherited by cancer cells, thus making it an attractive target for anticancer therapeutics. My research project aims to investigate novel therapeutic strategies that bypass resistance mechanisms associated with decreased expression of specific cell death activators in AMKL models. High-fatality AMKL models have been generated in our lab to emulate the human pathophysiology in the context of mice. I will engineer cell death-resistant models with a gene editing tool. The resistant models will then be treated with bioactive molecules to identify drugs that halt the progression of cancer by bypassing resistance mechanisms. There is a pressing need for treatments that successfully counter therapeutic resistance among pediatric leukemias to increase patient survival rates. My project offers a new perspective to identify novel compounds that target alternative cell death targets, consequently revealing new classes of drugs that could efficiently treat resistant pediatric AMKL.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Spilak, Julia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~